

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **April 5, 2019**

**LEXARIA BIOSCIENCE CORP.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction of  
incorporation)

**000-52138**

(Commission File Number)

**20-2000871**

(IRS Employer Identification No.)

**100 – 740 McCurdy Road, Kelowna, BC Canada**

(Address of principal executive offices)

**V1X 2P7**

(Zip Code)

Registrant's telephone number, including area code **(250) 765-6424**

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### **Item 5.02 Entry into Compensatory Arrangements**

On April 5, 2019 Lexaria Bioscience Corp. either directly or through its subsidiaries (collectively the “Lexaria Group”) entered into contractual agreements, having a retroactive effective date of January 1, 2019, with each of its President and Chief Executive Officer, either individually or via their respective wholly-owned company (the “Officers”). The entrance into these agreements provides the Lexaria Group with the security of having its key personnel committed to the Lexaria Group’s goals for a three year term. The combined compensation payable or issuable by the Lexaria Group to each of the Officers is as follows:

John Docherty – President – CDN\$300,000 annually (the “Docherty Compensation”); a bonus of up to 50% of the Docherty Compensation on the basis of certain performance criteria being met, as established by the board of directors; a one-time bonus equal to 2% of the consideration received for the sale of any subsidiary company of Lexaria Bioscience Corp. excluding certain circumstances; certain compensation to be paid upon a change of control excluding certain circumstances; and participation in the Lexaria Bioscience Corp. stock option plan.

Chris Bunka – Chief Executive Officer – CDN\$350,000 annually (the “Bunka Compensation”); a bonus of up to 50% of the Bunka Compensation on the basis of certain performance criteria being met, as established by the board of directors; a one-time bonus equal to 2% of the consideration received for the sale of any subsidiary company of Lexaria Bioscience Corp. excluding certain circumstances; certain compensation to be paid upon a change of control excluding certain circumstances; and participation in the Lexaria Bioscience Corp. stock option plan

#### **Item 8.01 Other Events**

Lexaria has, effective April 5, 2019, cancelled 1,140,000 stock options having exercise prices ranging from US\$0.10 to US\$2.06.

#### **Item 9.01 Financial Statements and Exhibits**

[99.1](#) [Press Release dated April 9, 2019](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LEXARIA BIOSCIENCE CORP.**

Date April 10, 2019

By: *“Chris Bunka”*

\_\_\_\_\_  
**Chris Bunka**

CEO, Principal Executive Officer

## Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options.

Kelowna, British Columbia – April 9, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has successfully negotiated renewal management contracts with Chief Executive Officer Chris Bunka and President John Docherty.

The new contracts are for 3-year terms and ensure that the Company can seamlessly pursue its business goals and create shareholder value while providing management continuity during this period of corporate growth. Specific details of the contracts can be found within regulatory filings.

Lexaria will always strive to provide excellence in management which is always aligned with the interests of shareholders.

Finally, Lexaria announces that, effective April 5, 2019, it has reached agreements with certain optionees to cancel 1,140,000 stock options having exercise prices ranging from US\$0.10 to US\$2.06.

### About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.  
[www.lexariabioscience.com](http://www.lexariabioscience.com)



For regular updates, connect with Lexaria on Twitter <http://twitter.com/lexariacorp>



and on Facebook <http://www.facebook.com/lexariabioscience/>

### FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.  
Alex Blanchard, Communications Manager  
(250)765-6424 Ext 202  
Or  
NetworkNewsWire (NNW)

---

www.NetworkNewsWire.com

#### FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&D is often unpredictable and unanticipated results could emerge from any study and have a material impact. There is no assurance that any planned corporate activity, scientific study, R&D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). TurboCBD™, DehydraTECH™ technology and ViPova™ products are not intended to diagnose, treat, cure or prevent any disease.

*The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.*

---